Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.45 |
| ▸ | ERN1 | O75460 | 8/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190751 | 0.92 | BRAF (0.49) | BRAFERN1LCKMAPK14FGFR1 | |
| SCHEMBL29353122 | 0.91 | ERN1 (0.42) | BRAFERN1MAPK8MAPK14 | |
| SCHEMBL22200339 | 0.91 | ERN1 (0.42) | BRAFERN1MAPK8MAPK14 | |
| SCHEMBL29354708 | 0.91 | ERN1 (0.42) | BRAFERN1MAPK14 | |
| SCHEMBL22200683 | 0.91 | ERN1 (0.47) | BRAFERN1MAPK8 | |
| SCHEMBL29356472 | 0.91 | ERN1 (0.47) | BRAFERN1MAPK8 | |
| SCHEMBL29355953 | 0.91 | ERN1 (0.48) | BRAFERN1MAPK8 | |
| SCHEMBL29353878 | 0.85 | ERN1 (0.51) | BRAFERN1 | |
| SCHEMBL22200539 | 0.85 | ERN1 (0.51) | BRAFERN1 | |
| SCHEMBL22191320 | 0.84 | ERN1 (0.42) | BRAFERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BRAF 563/4885ERN1 3167/4885MAPK8 925/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | BRAF 563/4885ERN1 3167/4885MAPK8 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.